

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 October 2002 (24.10.2002)

PCT

(10) International Publication Number
WO 02/083262 A1

(51) International Patent Classification⁷: **B01D 21/26**,
36/00, G01N 33/537, 33/567

[US/US]; 2275 Groberg Street #4, Mounds View, MN
55112 (US).

(21) International Application Number: PCT/US02/07079

(74) Agent: **ELLINGER, Mark, S.**; Fish & Richardson P.C.,
P.A., 60 South Sixth Street, Suite 3300, Minneapolis, MN
55402 (US).

(22) International Filing Date: 7 March 2002 (07.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/282,823 10 April 2001 (10.04.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/282,823 (CIP)
Filed on 10 April 2001 (10.04.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **BIOER-
GONOMICS, INC.** [US/US]; 4280 Centerville Road, St.
Paul, MN 55127 (US).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLLINS, Daniel,
P.** [US/US]; 6656 Pelican Place, Lino Lakes, MN 55014
(US). **SHAUT, David, M.** [US/US]; 858 Winterberry
Court, Woodbury, MN 55125 (US). **HAPKE, Joel, H.**

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: CELL SEPARATION COMPOSITIONS AND METHODS

(57) Abstract: The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield.



WO 02/083262 A1

Cell Separation Compositions and Methods

TECHNICAL FIELD

The present invention relates to compositions and methods for separating cells.

BACKGROUND

5 Many conventional blood cell isolation procedures include a preliminary bulk separation of erythrocytic and granulocytic components by density-gradient sedimentation. Density-gradient separation relies on small differences in the density of different cell types causing them to segregate at different levels in a fluid medium of variable density. Differences in density between the cell types can be small, and
10 individual cells types can be heterogeneous in size and density. Consequently, particular cell types can become distributed throughout a density-gradient medium rather than precisely segregating at a discrete area in the density medium. This phenomenon can result in poor recovery of desired cells and/or contamination with undesired cell types. In procedures that enrich for rare blood cell types such as hematopoietic progenitor cells,
15 density-gradient sedimentation generally results in poor yields. For example, using conventional density-gradient methods to isolate progenitor cells (e.g., CD34+ hematopoietic stem cells) from umbilical cord blood reportedly results in a significant loss of the desired stem cells. See e.g., Wagner, J.E., Am J Ped Hematol Oncol 15:169 (1993). As another example, using conventional density-gradient methods to isolate
20 lymphocytes reportedly results in selective loss of particular lymphocyte subsets. See e.g., Collins, D.P., J Immunol Methods 243:125 (2000).

 Increasing the recovery of rare cell types from donor tissue could dramatically improve the success of transplant and immune therapies (e.g., bone marrow transplants, stem cell-based gene therapy, and immune cell therapy), the success of which apparently
25 is related to the actual number of the cells being used for therapy.

SUMMARY

The invention provides compositions and methods for separating cells. The disclosed compositions and methods can be used, for example, to efficiently prepare cells for tissue culture, immunophenotypic characterization, other diagnostic testing, further
5 purification, and therapeutic administration.

Methods of the invention involve for contacting a blood cell-containing sample (e.g., peripheral blood sample, umbilical cord sample, and bone marrow sample) with a cell separation composition. Without being bound by a particular mechanism, compositions of the invention can selectively agglutinate cells via interaction with cell
10 surface antigens and/or by stimulating cell-cell adherence (e.g., via increased expression of cell surface adhesion factors). Agglutinated cells partition away from unagglutinated cells, which remain in solution. Cells can be recovered from either or both the agglutinate or the supernatant phase.

The disclosed compositions and methods can be used to isolate and enrich for a
15 variety of cell types, including, for example, T lymphocytes, T helper cells, T suppressor cells, B cells, hematopoietic stem cells, circulating embryonic stem cells, circulating fetal cells in maternal circulation, and circulating metastatic tumor cells. The disclosed compositions and methods can be used in the context of allogenic and autologous transplantation. In the context of autologous transplantation, the disclosed compositions
20 and methods can be used, for example, to remove undesired cells such as metastatic cancer cells from a patient's blood or bone marrow. Desirable cells (e.g., hematopoietic stem cells) then can be returned back to a patient without, or substantially free of, life-threatening tumor cells. The disclosed compositions and methods can be applied to cells of any mammal, including humans, non-human primates, rodents, swine, bovines and
25 equines.

Cell separation compositions can contain dextran, anti-glycophorin A antibody, as well as antibodies against cell surface antigens such as CD9, CD15, CD2, CD3, CD4, CD8, CD72, CD16, CD41a, HLA Class I, HLA-DR, CD29, CD11a, CD11b, CD11c, CD19, CD20, CD23, CD39, CD40, CD43, CD44, CDw49d, CD53, CD54, CD62L,
30 CD63, CD66, CD67, CD81, CD82, CD99, CD100, Leu-13, TPA-1, or surface Ig, and

combinations thereof. Cell separation compositions can contain antibodies against surface antigens of other types of cells (e.g., cell surface proteins of tumor cells).

Antibodies against cell surface antigens can be included in a cell separation composition in either or both soluble and substrate-bound forms. Antibodies can be bound to substrates such as latex microparticles, acid-etched glass particles, aggregated polypeptides, polysaccharides, avidin particles, or biotinylated agarose gel particles. Antibodies in cell separation compositions can be monoclonal and can be IgM or IgG antibodies. In some embodiments, a cell separation contains antihuman antibody. The concentration of a soluble antibody in a cell separation composition can be about 0.1 mg / l to about 15 mg / l. Substrate-bound antibodies can be included in a cell separation composition at a concentration between about 0.1 and about 50.0×10^9 particles/l.

Cell separation compositions also can contain heparin, divalent cations (e.g., Ca^{+2} , Mg^{+2}), and phosphate buffered saline. In some embodiments, compositions have a pH between 6.8 to 7.8 (e.g., between 7.2 to 7.4).

The invention also provides kits containing components of a cell separation composition and packaging material. Kits can include a blood collection vessel such as a blood bag or a vacuum tube.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

DETAILED DESCRIPTION

The invention features compositions and methods for separating cells. Compositions of the invention can be used to selectively agglutinate cells from blood

cell-containing samples. Without being bound by a particular mechanism, compositions of the invention can agglutinate cells via interaction with cell surface antigens and/or by stimulating expression of cell surface adhesion factors such as LFA-1 (Lymphocyte Function-Associated Antigen-1, CD11a/CD18) and ICAM-1 (Intercellular Adhesion Molecule-1, CD54). Agglutinated cells partition away from unagglutinated cells, which remain in solution. Cells can be recovered from the supernatant or from the agglutinate.

Cell Separation Compositions

A cell separation composition in accord with the invention can contain dextran and one or more antibodies against (i.e., that have specific binding affinity for) a cell surface antigen.

Dextran is a polysaccharide consisting of glucose units linked predominantly in alpha (1 to 6) mode. Dextran can cause stacking of erythrocytes (i.e., rouleau formation) and thereby facilitate the removal of erythroid cells from solution. Antibodies against cell surface antigens can facilitate the removal of blood cells from solution via homotypic agglutination (i.e., agglutination of cells of the same cell type) and/or heterotypic agglutination (i.e., agglutination of cells of different cell types).

Cell separation compositions can contain antibodies against blood cell surface antigens including, for example, glycophorin A, CD15, CD9, CD2, CD3, CD4, CD8, CD72, CD16, CD41a, HLA Class I, HLA-DR, CD29, CD11a, CD11b, CD11c, CD19, CD20, CD23, CD39, CD40, CD43, CD44, CDw49d, CD53, CD54, CD62L, CD63, CD66, CD67, CD81, CD82, CD99, CD100, Leu-13, TPA-1, surface Ig, and combinations thereof. Thus, cell separation compositions can be formulated to selectively agglutinate particular types of blood cells.

In some embodiments, a cell separation composition includes antibodies against glycophorin A. Anti-glycophorin A antibodies can facilitate the removal of red cells from solution by at least two mechanisms. First, anti-glycophorin A antibodies can cause homotypic agglutination of erythrocytes since glycophorin A is the major surface glycoprotein on erythrocytes. In addition, anti-glycophorin A antibodies also can stabilize dextran-mediated rouleau formation. Exemplary monoclonal anti-glycophorin A antibodies include, without limitation, 107FMN (Murine IgG1 Isotype), YTH89.1 (Rat

IgG2b Isotype), and E4 (Murine IgM Isotype). See e.g., M. Vanderlaan et al., *Molecular Immunology* 20:1353 (1983); Telen M. J. and Bolk, T. A., *Transfusion* 27: 309 (1987); and Outram S. et al., *Leukocyte Research*. 12:651 (1988).

In some embodiments, a cell separation composition includes antibodies against
5 CD15. Anti-CD15 antibodies can cause homotypic agglutination of granulocytes by crosslinking CD15 molecules that are present on the surface of granulocytes. Anti CD15 antibodies also can cause homotypic and heterotypic agglutination of granulocytes with monocytes, NK-cells and B-cells by stimulating expression of adhesion molecules (e.g., L-selectin and beta-2 integrin) on the surface of granulocytes that interact with adhesion
10 molecules on monocytes, NK-cells and B-cells. Heterotypic agglutination of these cell types can facilitate the removal of these cells from solution along with red cell components. Exemplary monoclonal anti-CD15 antibodies include, without limitation, AHN1.1 (Murine IgM Isotype), FMC-10 (Murine IgM Isotype), BU-28 (Murine IgM Isotype), MEM-157 (Murine IgM Isotype), MEM-158 (Murine IgM Isotype), MEM-167
15 (Murine IgM Isotype). See e.g., Leukocyte typing IV (1989); Leukocyte typing II (1984); Leukocyte typing VI (1995); Solter D. et al., *Proceedings of National Academy of Sciences USA* 75:5565 (1978); Kannagi R. et al., *Journal of Biological Chemistry* 257:14865 (1982); Magnani, J. L. et al., *Archives of Biochemistry and Biophysics* 233:501 (1984); Eggens I. et al., *Journal of Biological Chemistry* 264:9476 (1989).

In some embodiments, a cell separation composition includes antibodies against
20 CD9. Anti-CD9 antibodies can cause homotypic agglutination of platelets. Anti-CD9 antibodies also can cause heterotypic agglutination of granulocytes and monocytes via platelets that have adhered to the surface of granulocytes and monocytes. CD9 antibodies can promote the expression of platelet l-selectin, which facilitates the binding of platelets
25 to leukocyte cell surfaces. Thus, anti-CD9 antibodies can promote multiple cell-cell linkages and thereby facilitate agglutination and removal from solution. Exemplary monoclonal anti-CD9 antibodies include, without limitation, MEM-61 (Murine IgG1 Isotype), MEM-62 (Murine IgG1 Isotype), MEM-192 (Murine IgM Isotype), FMC-8 (Murine IgG2a Isotype), SN4 (Murine IgG1 Isotype), BU-16 (Murine IgG2a Isotype).
30 See e.g., Leukocyte typing VI (1995); Leukocyte typing II (1984); Von dem Bourne A. E. G. Kr. and Moderman P. N. (1989) In Leukocyte typing IV (ed. W. Knapp, et al), pp. 989

– 92. Oxford University Press, Oxford; Jennings, L. K., et al. In Leukocyte typing V, ed. S. F. Schlossmann et al., pp. 1249 – 51. Oxford University Press, Oxford (1995); Lanza F. et al., Journal of Biological Chemistry 266:10638 (1991); Wright et al., Immunology Today 15:588 (1994); Rubinstein E. et al., Seminars in Thrombosis and Hemostasis 21:10
5 (1995).

In some embodiments, a cell separation composition contains antibodies against CD41, which can selectively agglutinate platelets. In some embodiments, a cell separation composition contains antibodies against CD3, which can selectively agglutinate T-cells. In some embodiments, a cell separation composition contains
10 antibodies against CD2, which can selectively agglutinate T-cells and NK cells. In some embodiments, a cell separation composition contains antibodies against CD72, which can selectively agglutinate B-cells. In some embodiments, a cell separation composition contains antibodies against CD16, which can selectively agglutinate NK cells and neutrophilic granulocytes.

As mentioned above, cell separation compositions can be formulated to selectively agglutinate particular blood cells. As an example, a cell separation composition containing antibodies against glycophorin A, CD15, and CD9 can facilitate the agglutination of erythrocytes, granulocytes, NK cells, B cells, and platelets. T cells, NK cells and rare precursor cells then can be recovered from solution. If the formulation
15 also contained an antibody against CD3, T cells also could be agglutinated, and NK cells and rare precursors could be recovered from solution.

Cell separation compositions can contain antibodies against surface antigens of other types of cells (e.g., cell surface proteins of tumor cells). Those of skill in the art can use routine methods to prepare antibodies against cell surface antigens of blood, and
25 other, cells from humans and other mammals, including, for example, non-human primates, rodents (e.g., mice, rats, hamsters, rabbits and guinea pigs), swine, bovines, and equines.

Typically, antibodies used in the composition are monoclonal antibodies, which are homogeneous populations of antibodies to a particular epitope contained within an antigen. Suitable monoclonal antibodies are commercially available, or can be prepared
30 using standard hybridoma technology. In particular, monoclonal antibodies can be

obtained by techniques that provide for the production of antibody molecules by continuous cell lines in culture, including the technique described by Kohler, G. et al., Nature, 1975, 256:495, the human B-cell hybridoma technique (Kosbor et al., Immunology Today 4:72 (1983); Cole et al., Proc. Natl. Acad. Sci. USA 80:2026 (1983)),
5 and the EBV-hybridoma technique (Cole et al., "Monoclonal Antibodies and Cancer Therapy," Alan R. Liss, Inc., pp. 77-96 (1983)).

Antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. Antibodies of the IgG and IgM isotypes are particularly useful in cell separation compositions of the invention. Pentameric IgM antibodies
10 contain more antigen binding sites than IgG antibodies and can, in some cases (e.g., anti-glycophorin A and anti-CD15), be particularly useful for cell separation reagents. In other cases (e.g., anti-CD9 antibodies), antibodies of the IgG isotype are particularly useful for stimulating homotypic and/or heterotypic agglutination.

Antibodies against cell surface antigens can be provided in liquid phase (i.e.,
15 soluble). Liquid phase antibodies typically are provided in a cell separation composition at a concentration between about 0.1 and about 15 mg/l (e.g., between 0.25 to 10, 0.25 to 1, 0.5 to 2, 1 to 2, 4 to 8, 5 to 10 mg/l).

Antibodies against cell surface antigens also can be provided in association with a solid phase (i.e., substrate-bound). Antibodies against different cell surface antigens can
20 be covalently linked to a solid phase to promote crosslinking of cell surface molecules and activation of cell surface adhesion molecules. The use of substrate-bound antibodies can facilitate cell separation (e.g., by virtue of the mass that the particles contribute to agglutinated cells, or by virtue of properties useful for purification).

In some embodiments, the solid phase with which an substrate-bound antibody is
25 associated is particulate. In some embodiments, an antibody is bound to a latex microparticle such as a paramagnetic bead (e.g., via biotin-avidin linkage, covalent linkage to COO groups on polystyrene beads, or covalent linkage to NH₂ groups on modified beads). In some embodiments, an antibody is bound to an acid-etched glass particle (e.g., via biotin-avidin linkage). In some embodiments, an antibody is bound to
30 an aggregated polypeptide such as aggregated bovine serum albumin (e.g., via biotin-avidin linkage, or covalent linkage to polypeptide COO groups or NH₂ groups). In some

embodiments, an antibody is covalently linked to a polysaccharide such as high molecular weight (e.g., $>1,000,000 M_r$) dextran sulfate. In some embodiments, biotinylated antibodies are linked to avidin particles, creating tetrameric complexes having four antibody molecules per avidin molecule. In some embodiments, antibodies are bound to biotinylated agarose gel particles (One Cell Systems, Cambridge, MA, U.S.A.) via biotin-avidin-biotinylated antibody linkages. Such particles typically are about 300-500 microns in size, and can be created in a sonicating water bath or in a rapidly mixed water bath.

Cell-substrate particles (i.e., particles including cells and substrate-bound antibodies) can sediment from solution as an agglutinate. Cell-substrate particles also can be removed from solution by, for example, an applied magnetic field, as when the particle is a paramagnetic bead. Substrate-bound antibodies typically are provided in a cell separation composition at a concentration between about 0.1 and about 50.0×10^9 particles/l (e.g., between 0.25 to 10.0×10^9 , 1 to 20.0×10^9 , 2 to 10.0×10^9 , 0.5 to 2×10^9 , 2 to 5×10^9 , 5 to 10×10^9 , and 10 to 30×10^9 particles/l), where particles refers to solid phase particles having antibodies bound thereto.

Cell separation compositions also can contain divalent cations (e.g., Ca^{+2} and Mg^{+2}). Divalent cations can be provided, for example, by a balanced salt solution (e.g., Hank's balanced salt solution). Ca^{+2} ions reportedly are important for selectin-mediated and integrin-mediated cell-cell adherence.

Cell separation compositions of the invention also can contain an anticoagulant such as heparin. Heparin can prevent clotting and non-specific cell loss associated with clotting in a high calcium environment. Heparin also promotes platelet clumping. Clumped platelets can adhere to granulocytes and monocytes and thereby enhance heterotypic agglutination more so than single platelets. Heparin can be supplied as a heparin salt (e.g., sodium heparin, lithium heparin, or potassium heparin).

Cell Separation Methods

The disclosed compositions can be used, for example, to efficiently prepare cells for tissue culture, immunophenotypic characterization, other diagnostic testing, further purification, and therapeutic administration. Without being bound by a particular mechanism, compositions of the invention can selectively agglutinate cells via interaction

with cell surface antigens and/or by stimulating cell-cell adherence (e.g., via increased expression of cell surface adhesion factors). Agglutinated cells partition away from unagglutinated cells, which remain in solution.

After agglutination, unagglutinated cells can be recovered from the solution phase.

- 5 Cells also can be recovered from the agglutinate. Agglutinated cells can be dissociated by, for example, transferring the cells into buffers that contain divalent cation chelators such as EDTA or EGTA. Cells recovered from the agglutinate can be further separated by using antibodies against cell surface antigens. Cells can be recovered from a gel
10 microparticle-antibody-cell agglutinate by heating the agglutinate to a temperature just above the melting point.

- The disclosed compositions can be used to separate cells from a variety of samples, including peripheral blood (e.g., obtained by venipuncture), umbilical cord blood (e.g., obtained post-gravida), and bone marrow (e.g., from aspirate). Blood cell-
15 containing samples can be contacted with a cell separation composition to cause agglutination of particular types of cells. For example, erythrocytes and differentiated myeloid blood constituents can be selectively agglutinated using cell separation compositions containing antibodies to surface antigens of these cells. The disclosed compositions and methods can be used to isolate and enrich for a variety of cell types, including, for example, T lymphocytes, T helper cells, T suppressor cells, B cells,
20 hematopoietic stem cells, circulating embryonic stem cells, circulating fetal cells in maternal circulation, and circulating metastatic tumor cells. The disclosed compositions can be used to agglutinate cells of any mammal, including humans, non-human primates, rodents, swine, bovines and equines.

- The disclosed compositions and methods can be used in the context of allogenic
25 and autologous transplantation. In the context of autologous transplantation, the disclosed compositions and methods can be used, for example, to remove undesired cells such as metastatic cancer cells from a patient's blood or bone marrow. Desirable cells (e.g., hematopoietic stem cells) then can be returned back to a patient without, or substantially free of, life-threatening tumor cells.

- 30 Cell separation compositions containing antibodies against cell surface proteins of tumor cells can be used to purge tumor cells from a patient's blood or bone marrow.

Such compositions also can be used for diagnostic procedures to, for example, obtain and detect tumor cells in an agglutinate, where they are concentrated and are therefore more easily detectable than in circulating blood or in bone marrow. A cell separation composition containing antibodies against the receptor for epithelial growth factor can be used to agglutinate tumor cells derived from epithelial tumors (e.g., head and neck tumors). A cell separation composition containing antibodies against estrogen receptors can be used to agglutinate tumor cells derived from breast and ovarian tumors. A cell separation composition containing antibodies against surface immunoglobulins can be used to agglutinate tumor cells associated with chronic lymphocytic leukemia, plasmacytoma, and multiple myeloma. Breast carcinoma cells express CD15 on their cell surface, and can be purged from bone marrow using cell separations that contain antibodies against CD15. Other formulas can be made on the basis of cell type and cell surface proteins to obtain or deplete metastatic tumor cells derived from other carcinomas (e.g., erythroleukemia, endothelial carcinoma, and gastrointestinal carcinoma) from a patient's blood or bone marrow.

Cell Separation Kits

A cell separation composition can be combined with packaging material and sold as a kit. The components of a cell separation composition can be packaged individually or in combination with one another. In some embodiments, the packaging material includes a blood collection vessel (e.g., blood bag, vacuum tube). The packaging material included in a kit typically contains instructions or a label describing how the cell separation composition can be used to agglutinate particular types of cells. Components and methods for producing such kits are well known.

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1: Separating blood cells.

This example describes the general method by which cells were separated using the cell separation reagents described below. An equal volume of a cell separation

reagent (i.e., 25 ml) was combined with an equal volume of an EDTA anti-coagulated heparinized peripheral blood sample (i.e., 25 ml) in a 50 ml conical tube. Samples containing white blood cell counts greater than 20×10^6 cells / ml were combined one part blood with two parts cell separation reagent. Tubes were gently mixed on a rocker
5 platform for 30 to 45 minutes at room temperature. Tubes were stood upright in a rack for 30 to 50 minutes to permit agglutinated cells to partition away from unagglutinated cells, which remained in solution. Without disturbing the agglutinate, a pipette was used to recover unagglutinated cells from the supernatant. Recovered cells were washed in 25 ml PBS and centrifuged at $500 \times g$ for 7 minutes. The cell pellet was resuspended in 4 ml
10 PBS.

Cells also were recovered from the agglutinate using a hypotonic lysing solution containing ethylenediaminetetraacetic acid (EDTA) and ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA). Agglutinated cells were treated with 25 ml VitaLyseTM (BioErgonomics, St. Paul, MN) and vortexed. After 10 minutes,
15 cells either were exposed to an applied magnetic field to recover cells associated with antibodies bound to paramagnetic beads, or were centrifuged at $500 \times g$ for 7 minutes and the supernatant was removed. In either case, cells were resuspended in 4 ml PBS.

Recoveries of erythrocytes, leukocytes, lymphocytes, monocytes, granulocytes, T cells, B cells, and NK cells were determined by flow cytometry and immunophenotyping.
20 Prior to flow cytometry, leukocyte recovery (i.e., white blood cell count) was determined using a Coulter Onyx Hematology Analyzer, and samples were adjusted with PBS to a cell count of 1×10^7 cells/ml. 100 ul aliquots of volume-adjusted sample were stained at room temperature in the dark for 15 to 30 minutes with either FITC labeled anti-CD3 antibodies (reactive to T cells), PE labeled anti-CD19 antibodies (reactive to B cells), or
25 PE labeled anti-CD16 antibodies (reactive to NK cells). 2 ml of PBS was added to each sample, and the sample was then vortexed and centrifuged to pellet cells. Supernatants were discarded, and cell pellets were vortexed and resuspended in 0.5 ml PBS. Stained and unstained cells were analyzed by flow cytometry using a Coulter XL flow cytometer. Erythrocytes, leukocytes, lymphocytes, monocytes, granulocytes and platelets were
30 identified on the basis of diagnostic forward and side light scatter properties. B cells, T

cells, and NK cells were identified on the basis of light scattering and staining by labeled antibodies.

Example 2: Erythrocyte agglutination.

- 5 The reagent described in Table 1 was used to separate cells according to the method described in Example 1.

Table 1

Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50 ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody clone E4)	1.0 mg/l

- Results of a separation are shown in Table 2. Erythrocytes were depleted 99.7% from the supernatant. Lymphocytes (T cells, B cells, and NK cells) were enriched in the supernatant relative to the monocytes and granulocytes.
- 10

Table 2

	Before separation	After separation
Erythrocytes per ml	4.41×10^9	0.015×10^9
Leukocytes per ml	5.9×10^6	5.3×10^6
Lymphocytes (%)	28.7	41.9
Monocytes (%)	8.69	4.78
Granulocytes (%)	62.5	52.6
T Cells (CD3+)	19.7	31.8
B Cells (CD19+)	4.46	5.42
NK Cells (CD16+)	3.15	5.9

Example 3: Erythrocyte and CD2+ cell agglutination.

The reagent described in Table 3 was used to separate cells according to the method described in Example 1.

15

Table 3

Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50 ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	1.0 mg/l
Anti-human CD2 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD2, clone d118.10.1)	14.02 x 10 ⁹ particles/l

Results of a separation are shown in Table 4. In the supernatant, erythrocytes were depleted 99.7%, T cells were depleted 95.1%, and NK cells were depleted 69.1%. B cells were enriched in the supernatant relative to other cells.

Table 4

	Before separation	After separation
Erythrocytes per ml	4.41 x 10 ⁹	0.014 x 10 ⁹
Leukocytes per ml	5.9 x 10 ⁶	2.63 x 10 ⁶
Lymphocytes (%)	28.7	16.0
Monocytes (%)	8.69	6.04
Granulocytes (%)	62.5	75.6
T Cells (CD3+)	19.7	3.3
B Cells (CD19+)	4.46	9.63
NK Cells (CD16+)	3.15	4.32

5

Example 4: Erythrocyte and CD72+ cell agglutination.

The reagent described in Table 5 was used to separate cells according to the method described in Example 1.

Table 5

Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50 ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	1.0 mg/l
Anti-human CD72 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD72, clone BU40)	2.63 x 10 ⁶ particles/ml

10

Results of a separation are shown in Table 6. In the supernatant, erythrocytes were depleted 99.5%, and B cells were depleted 81.6%.

Table 6

	Before separation	After separation
Erythrocytes per ml	4.41×10^9	0.021×10^9
Leukocytes per ml	5.9×10^6	3.2×10^6
Lymphocytes (%)	28.7	47.0
Monocytes (%)	8.69	4.78
Granulocytes (%)	62.5	47.7
T Cells (CD3+)	19.7	41.3
B Cells (CD19+)	4.46	2.75
NK Cells (CD16+)	3.15	4.77

Example 5: Erythrocyte, CD15+ cell, and CD9+ cell agglutination.

- 5 The reagent described in Table 7 was used to separate cells according to the method described in Example 1.

Table 7

Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50 ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	0.1 - 15 mg/l (preferably about 1.0 mg/l)
Anti-CD15 (murine IgM monoclonal antibody, clone MEM-158)	0.1 - 15 mg/l (preferably about 1.0 mg/l)
Anti-CD9 (murine IgG monoclonal antibody, clone MEM-61)	0.1 - 15 mg/l (preferably about 1.0 mg/l)

- 10 Results of a separation are shown in Table 8. In the supernatant, erythrocytes were depleted 99.9%, monocytes and granulocytes were depleted 99.8%, B cells were depleted 74%, and NK cells were depleted 64.9%. In addition, platelets, present in the supernatant at 226×10^6 /ml before separation, were depleted to 1.4×10^6 /ml for 99.4% depletion.

Table 8

	Before separation	After separation
Erythrocytes per ml	4.41×10^9	0.006×10^9
Leukocytes per ml	5.9×10^6	1.53×10^6
Lymphocytes (%)	28.7	99.0
Monocytes (%)	8.69	0.12
Granulocytes (%)	62.5	.083
T Cells (CD3+)	19.7	83.2
B Cells (CD19+)	4.46	8.10
NK Cells (CD16+)	3.15	8.43

Example 6: Erythrocyte, CD15+ cell, CD9+ cell, and CD2+ cell agglutination.

The reagent described in Table 9 was used to separate cells according to the method described in Example 1.

Table 9

Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50 ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	1 mg/l
Anti-CD15 (murine IgM monoclonal antibody, clone MEM-158)	1 mg/l
Anti-CD9 (murine IgG monoclonal antibody, clone MEM-61)	1 mg/l
Anti-human CD2 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD2, clone d118.10.1)	14.02×10^9 particles/l

5

Results of a separation are shown in Table 10. In the supernatant, erythrocytes were depleted 99.9%, monocytes and granulocytes were depleted 99.9%, B cells were depleted 16.8%, NK cells were depleted 29%, and T cells were depleted 91.5%. In addition, platelets, present in the supernatant at 226×10^6 /ml before separation, were

10

depleted to 0.3×10^6 /ml for 99.9% depletion.

Table 10

	Before separation	After separation
Erythrocytes per ml	4.41×10^9	0.005×10^9
Leukocytes per ml	5.9×10^6	1.26×10^6
Lymphocytes (%)	28.7	99.8
Monocytes (%)	8.69	0.06
Granulocytes (%)	62.5	0.09
T Cells (CD3+)	19.7	6.78
B Cells (CD19+)	4.46	69.5
NK Cells (CD16+)	3.15	20.7

Example 7: Erythrocyte, CD15+ cell, CD9+ cell, and CD72+ cell agglutination.

The reagent described in Table 11 was used to separate cells according to the method described in Example 1.

Table 11

Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50 ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	1 mg/l
Anti-CD15 (murine IgM monoclonal antibody, clone MEM-158)	1 mg/l
Anti-CD9 (murine IgG monoclonal antibody, clone MEM-61)	1 mg/l
Anti-human CD72 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD72, clone BU40)	2.63×10^9 particles/l

5

Results of a separation are shown in Table 12. In the supernatant, erythrocytes were depleted 99.9%, monocytes were depleted beyond detection, granulocytes were depleted 99.97%, B cells were depleted 97.2%, NK cells were depleted 54.9%. In addition, platelets, present in the supernatant at 226×10^6 /ml before separation, were

10

depleted to 0.1×10^6 /ml for 99.96% depletion.

Table 12

	Before separation	After separation
Erythrocytes per ml	4.41×10^9	0.006×10^9
Leukocytes per ml	5.9×10^6	2.3×10^6
Lymphocytes (%)	28.7	99.9
Monocytes (%)	8.69	0
Granulocytes (%)	62.5	0.1
T Cells (CD3+)	19.7	92.4
B Cells (CD19+)	4.46	0.59
NK Cells (CD16+)	3.15	7.02

Example 8: Erythrocyte, CD15+ cell, CD9+ cell, CD19+ cell, and CD16+ cell agglutination.

5 The reagent described in Table 13 was used to separate cells according to the method described in Example 1. T cells and CD3+ cells were recovered from the supernatant. B cells and granulocytes are recovered from the agglutinate.

Table 13

Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD15 (murine IgM monoclonal antibody, clone MEM-158)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD9 (murine IgM monoclonal antibody, clone MEM-61)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-CD19 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD19, clone HIB19)	$0.1-30.0 \times 10^9$ particles/l (preferably about 19.8×10^9 particles/l)
Anti-CD16 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD16, clone 3G8)	5.5×10^{11} particles/l

Example 9: Erythrocyte, CD15+ cell, CD9+ cell, CD19+ cell, CD16+ cell, and CD4+ cell agglutination.

10 The reagent described in Table 14 was used to separate cells according to the method described in Example 1. CD8+ cells were recovered from the supernatant.

Table 14	
Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD15 (murine IgM monoclonal antibody, clone MEM-158)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD9 (murine IgM monoclonal antibody, clone MEM-61)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-CD19 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD19, clone HIB19)	0.1-30.0 x 10 ⁹ particles/l (preferably about 19.8 x 10 ⁹ particles/l)
Anti-CD16 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD16, clone 3G8)	5.5 x 10 ¹¹ particles/l
Anti-CD4 paramagnetic agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD4, clone RFT4-γ or clone QS4120)	1.2 x 10 ¹⁰ particles/l

Example 10: Erythrocyte, CD15+ cell, CD9+ cell, CD19+ cell, CD16+ cell, and CD8+ cell agglutination.

5

The reagent described in Table 15 is used to separate cells according to the method described in Example 1. CD4+ cells are recovered from the supernatant.

10

15

Table 15	
Dextran (Average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50ml/l
Anti-human glycoporphin A (murine IgM monoclonal Antibody) clone E4	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD15 (murine IgM monoclonal Antibody) (clone MEM-158)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD9 (murine IgM monoclonal antibody) (clone MEM-61)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-CD19 agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD19 (clone HIB19)	0.1-30.0 x 10 ⁹ particles/l (preferably about 19.8 x 10 ⁹ particles/l)
Anti-CD16 agglutination particle (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD16 (clone 3G8)	5.5 x 10 ¹¹ particles/l
Anti-CD8 agglutination particle (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD8 (clone HIT8a)	7.92 x 10 ⁹ particles/l

Example 11: Erythrocyte, CD15+ cell, CD9+ cell, CD19+ cell, and CD2+ cell agglutination.

5

The reagent described in Table 16 was used to separate cells according to the method described in Example 1. CD34+ cells were recovered from the supernatant at >50% purity and >80% yield.

10

15

Table 16	
Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD15 (murine IgM monoclonal antibody, clone MEM-158)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD9 (murine IgM monoclonal antibody, clone MEM-61)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti- CD19 agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD19, clone HIB19)	0.1-30.0 x 10 ⁹ particles/l (preferably about 19.8 x 10 ⁹ particles/l)
Anti-CD2 agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD2, clone d118.10.1)	0.1-30.0 x 10 ⁹ particles/l (preferably about 3.0 x 10 ¹⁰ particles/l)

Example 12: Erythrocyte, CD15+ cell, CD9+ cell, CD2+ cell, and CD16+ cell agglutination.

- 5 The reagent described in Table 17 was used to separate cells according to the method described in Example 1. B cells were recovered from the supernatant.

Table 17	
Dextran (average molecular weight 413,000)	20 g/l
Dulbecco's phosphate buffered saline (10X)	100 ml/l
Sodium Heparin (10,000 units/ml)	1 ml/l
Hank's balanced salt solution (pH 7.2-7.4)	50ml/l
Anti-human glycophorin A (murine IgM monoclonal antibody, clone E4)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD15 (murine IgM monoclonal antibody, clone MEM-158)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-human CD9 (murine IgM monoclonal antibody, clone MEM-61)	0.1-15 mg/l (preferably about 1.0 mg/l)
Anti-CD2 agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD2, clone d118.10.1)	0.1-30.0 x 10 ⁹ particles/l (preferably about 3.0 x 10 ¹⁰ particles/l)
Anti-CD16 agglutination particles (avidin-coated 4.3 micron diameter paramagnetic polystyrene particles labeled with saturating doses of biotin-labeled mouse anti-human CD16, clone 3G8)	5.5 x 10 ¹¹ particles/l

OTHER EMBODIMENTS

While the invention has been described in conjunction with the foregoing detailed description and examples, the foregoing description and examples are intended to illustrate and not to limit the scope of the invention, which is defined by the scope of the
5 appended claims. Other aspects, advantages, and modifications are within the scope of the claims.

WHAT IS CLAIMED IS:

1. A composition comprising:
 - a) dextran;
 - b) anti-glycophorin A antibody;
 - 5 c) anti-CD15 antibody;
 - d) anti-CD9 antibody; and
 - e) an antibody selected from the group consisting of anti-CD3 antibody, anti-CD72 antibody, anti-CD16 antibody, anti-CD4 antibody, anti-CD8 antibody, and anti-CD2 antibody.
- 10 2. The composition of claim 1, further comprising heparin.
3. The composition of claim 1, further comprising divalent cations.
- 15 4. The composition of claim 3, wherein said divalent cations are Ca^{+2} .
5. The composition of claim 3, wherein said divalent cations are Mg^{+2} .
6. The composition of claim 1, further comprising phosphate buffered saline.
- 20 7. The composition of claim 1, wherein the pH of said composition is between 6.8 to 7.8.
8. The composition of claim 1, wherein the pH of said composition is between 7.2 to 7.4.
- 25 9. The composition of claim 1, wherein said anti-glycophorin A antibody is monoclonal.
- 30 10. The composition of claim 1, wherein said anti-glycophorin A antibody is an IgM antibody.

11. The composition of claim 1, wherein said anti-glycophorin A antibody is an IgG antibody.
- 5 12. The composition of claim 1, wherein said anti-glycophorin A antibody is an anti-human glycophorin A antibody.
13. The composition of claim 1, wherein the concentration of said anti-glycophorin A antibody is about 0.1 mg / l to about 15 mg / l.
- 10 14. The composition of claim 1, wherein said anti-CD15 antibody is a monoclonal antibody.
- 15 15. The composition of claim 1, wherein said anti-CD15 antibody is an IgM antibody.
16. The composition of claim 1, wherein said anti-CD15 antibody is an IgG antibody.
17. The composition of claim 1, wherein said anti-CD15 antibody is an anti-human CD15 antibody.
- 20 18. The composition of claim 1, wherein the concentration of said anti-CD15 antibody is about 0.1 mg / l to about 15 mg / l.
- 25 19. The composition of claim 1, wherein said anti-CD9 antibody is a monoclonal antibody.
20. The composition of claim 1, wherein said anti-CD9 antibody is an IgM antibody.
- 30 21. The composition of claim 1, wherein said anti-CD9 antibody is an IgG antibody.

22. The composition of claim 1, wherein said anti-CD9 antibody is an anti-human CD9 antibody.
23. The composition of claim 1, wherein the concentration of said anti-CD9 antibody is
5 about 0.1 mg / l to about 15 mg / l.
24. A kit comprising a blood collection vessel and a cell separation composition, said
cell separation composition comprising:
- a) dextran;
 - 10 b) anti-glycophorin A antibody;
 - c) anti-CD15 antibody;
 - d) anti-CD9 antibody; and
 - e) an antibody selected from the group consisting of anti-CD3 antibody, anti-CD72
antibody, anti-CD16 antibody, anti-CD4 antibody, anti-CD8 antibody, and anti-
15 CD2 antibody.
25. The kit of claim 24, wherein said blood collection vessel is a blood bag.
26. The kit of claim 24 wherein said blood collection vessel is a vacuum tube.
20
27. A method for separating cells, said method comprising:
- a) contacting a blood cell-containing sample with a composition, said composition
comprising:
- i) dextran;
 - 25 ii) anti-glycophorin A antibody;
 - iii) anti-CD15 antibody;
 - iv) anti-CD9 antibody; and
 - v) an antibody selected from the group consisting of anti-CD3 antibody, anti-
CD72 antibody, anti-CD16 antibody, anti-CD4 antibody, anti-CD8
30 antibody, and anti-CD2 antibody; and

- b) allowing said sample to partition into an agglutinate and a supernatant phase;
and
- c) recovering said cells.

5 28. The method of claim 27, wherein said sample is derived from a human.

29. The method of claim 28, wherein said sample is a peripheral blood sample.

30. The method of claim 28, wherein said sample is an umbilical cord sample.

10

31. The method of claim 28, wherein said sample is a bone marrow sample.

32. The method of claim 28, wherein said cells are metastatic tumor cells.

15 33. The method of claim 28, wherein said cells are recovered from said supernatant phase.

34. The method of claim 33, wherein said cells are stem cells.

20 35. A composition comprising:

- a) dextran;
- b) anti-glycophorin A antibody; and
- c) a substrate-bound antibody against a cell surface antigen.

25 36. The composition of claim 35, wherein said substrate-bound antibody is bound to a latex microparticle.

37. The composition of claim 35, wherein said substrate-bound antibody is bound to an acid- etched glass particle.

30

38. The composition of claim 35, wherein said substrate-bound antibody is bound to an aggregated polypeptide,
39. The composition of claim 35, wherein said substrate-bound antibody is bound to a
5 polysaccharide.
40. The composition of claim 35, wherein said substrate-bound antibody is bound to an avidin particle.
- 10 41. The composition of claim 35, wherein said substrate-bound antibody is bound to a biotinylated agarose gel particle.
42. The composition of claim 35, wherein said antibody is anti-CD15.
- 15 43. The composition of claim 35, wherein said antibody is anti-CD9.
44. The composition of claim 35, wherein said antibody is anti-CD3.
45. The composition of claim 35, wherein said antibody is anti-CD72.
- 20 46. The composition of claim 35, wherein said antibody is anti-CD16.
47. The composition of claim 35, wherein said antibody is anti-CD4.
- 25 48. The composition of claim 35, wherein said antibody is anti-CD8.
49. The composition of claim 35, wherein said antibody is anti-CD2.
50. The composition of claim 35, wherein said antibody is anti-CD3.
- 30 51. The composition of claim 35, further comprising heparin.

52. The composition of claim 35, further comprising divalent cations.

53. The composition of claim 52, wherein said divalent cations are Ca^{+2} .

5

54. The composition of claim 52, wherein said divalent cations are Mg^{+2} .

55. The composition of claim 35, further comprising phosphate buffered saline.

10 56. The composition of claim 35, wherein the pH of said composition is between 6.8 to 7.8.

57. The composition of claim 35, wherein the pH of said composition is between 7.2 to 7.4.

15

58. The composition of claim 35, wherein said anti-glycophorin A antibody is monoclonal.

59. The composition of claim 35, wherein said anti-glycophorin A antibody is an IgM antibody.

20

60. The composition of claim 35, wherein said anti-glycophorin A antibody is an IgG antibody.

25 61. The composition of claim 35, wherein said anti-glycophorin A antibody is an anti-human glycophorin A antibody.

62. The composition of claim 35, wherein the concentration of said anti-glycophorin A antibody is about 0.1 mg / l to about 15 mg / l.

30

63. The composition of claim 35, wherein said anti-glycophorin A antibody is substrate-bound.
64. The composition of claim 42, wherein said anti-CD15 antibody is a monoclonal
5 antibody.
65. The composition of claim 42, wherein said anti-CD15 antibody is an IgM antibody.
66. The composition of claim 42, wherein said anti-CD15 antibody is an IgG antibody.
10
67. The composition of claim 42, wherein said anti-CD15 antibody is an anti-human
CD15 antibody.
68. The composition of claim 42, wherein the concentration of said anti-CD15 antibody
15 is about 0.1 mg / l to about 15 mg / l.
69. The composition of claim 42, wherein said anti-CD15 antibody is substrate-bound.
70. The composition of claim 43, wherein said anti-CD9 antibody is a monoclonal
20 antibody.
71. The composition of claim 43, wherein said anti-CD9 antibody is an IgM antibody.
72. The composition of claim 43, wherein said anti-CD9 antibody is an IgG antibody.
25
73. The composition of claim 43, wherein said anti-CD9 antibody is an anti-human
CD9 antibody.
74. The composition of claim 43, wherein the concentration of said anti-CD9 antibody
30 is about 0.1 mg / l to about 15 mg / l.

75. The composition of claim 43, wherein said anti-CD9 antibody is substrate-bound.

76. A kit comprising a blood collection vessel and a cell separation composition, said cell separation composition comprising:

- 5 a) dextran;
 b) anti-glycophorin A antibody; and
 c) a substrate-bound antibody against a cell surface antigen of a human cell.

77. The kit of claim 76, wherein said blood collection vessel is a blood bag.

10

78. The kit of claim 76, wherein said blood collection vessel is a vacuum tube.

79. A method for separating cells, said method comprising:

- 15 a) contacting a blood cell-containing sample with a composition, said composition comprising:
 i) dextran;
 ii) anti-glycophorin A antibody; and
 iii) a substrate-bound antibody against a cell surface antigen.
 b) allowing said sample to partition into an agglutinate and a supernatant phase;
20 and
 c) recovering said cells.

80. The method of claim 79, wherein said sample is derived from a human.

25 81. The method of claim 80, wherein said sample is a peripheral blood sample.

82. The method of claim 80, wherein said sample is an umbilical cord sample.

83. The method of claim 80, wherein said sample is a bone marrow sample.

30

84. The method of claim 80, wherein said cells are metastatic tumor cells.

85. The method of claim 80, wherein said cells are recovered from said supernatant phase.

5 86. The method of claim 85, wherein said cells are stem cells.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/07079

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : B01D 21/26, 36/00; G01N 33/537, 33/567

US CL : 435/7.23

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Continuation Sheet

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 6,153,113 A (GOODRICH et al.) 28 November 2000 (28.11.2000), see entire document.	27-34, 79-86 ----- 1-26, 35-78
X,P --- Y,P	US 6,280,622 B1 (GOODRICH et al.) 28 August 2001 (28.08.2001), see entire document.	1-26, 35-78 ----- 27-34, 79-89
Y	US 5,840,502 A (VAN VLASSELAER) 24 November 1998 (24.11.1998), see entire document.	1-86



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 May 2002 (20.05.2002)

Date of mailing of the international search report

14 JUN 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Gallene R. Zabel

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/07079

Continuation of B. FIELDS SEARCHED Item 1:

435/2, 7.21, 7.23, 7.24, 803; 436/514, 518, 523, 527, 531, 532, 824; 210/252, 257.1, 259, 417, 502, 781, 782, 739, 786, 787

专利名称(译)	细胞分离组合物和方法		
公开(公告)号	EP1377353A1	公开(公告)日	2004-01-07
申请号	EP2002725093	申请日	2002-03-07
申请(专利权)人(译)	BIOERGONOMICS INC.		
当前申请(专利权)人(译)	BIOE , INC		
[标]发明人	COLLINS DANIEL P SHAUT DAVID M HAPKE JOEL H		
发明人	COLLINS, DANIEL, P. SHAUT, DAVID, M. HAPKE, JOEL, H.		
IPC分类号	C12N1/02 A61K31/721 A61K31/727 B01D21/26 C12N5/00 G01N33/53 G01N33/537 G01N33/541 G01N33/543 G01N33/567 G01N33/569 B01D36/00		
CPC分类号	G01N33/537 C07K16/2896 C12N5/0087 G01N33/5094 G01N33/541 G01N33/566 G01N33/56966 Y10T436/101666 Y10T436/107497 Y10T436/25375		
代理机构(译)	法思博事务所		
优先权	60/282823 2001-04-10 US		
其他公开文献	EP1377353A4		
外部链接	Espacenet		

摘要(译)

本发明提供了用于细胞分离的组合物和方法。这些试剂和技术通过表面抗原识别特异性地凝集细胞，并且可以用于以高产率回收甚至稀有细胞类型。